Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population
Okinawa is the original Blue Zone, validated by nearly five decades of groundbreaking research by ORCLS, which led to the discovery of other "longevity hotspots" - areas of the world with high concentrations of where people live to exceptional ages, extending not only their lifespans but their healthspans. KLTO has preliminary data from ORCLS suggesting the human alpha-Klotho gene and its secreted alpha-Klotho protein isoform (s-KL) may contribute to healthy longevity and lifespan. As we grow old, α-Klotho blood and tissue levels decrease. The decrease in tissue levels precedes the onset of multiple pathologies and diseases of human organ systems. Importantly, replenishing the s-KL levels using gene therapy may help protect against neurodegenerative disorders, muscle loss, bone loss and heart, liver and kidney disfunction associated with aging.
Commenting on this significant opportunity, Dr. Joseph Sinkule, the CEO of KLTO, noted that "animal studies using the Klotho gene in degenerative neurological conditions produced extremely interesting results. KLTO and ORCLS scientists believe the maintenance of optimum blood levels of the Klotho protein in later life correlates with longevity, whereas lower blood levels are associated with premature aging and a propensity to develop certain neurological disorders. While results in animal studies do not always translate into success in human clinical studies, we were very encouraged by the exceptional results, and believe that our patent protected secreted s-KL protein isoform of the Klotho gene holds real promise for the development of effective treatments for neurological disorders, as well as other age-related disorders such as sarcopenia, osteoporosis, diabetes and various renal and cardiovascular disorders. We are confident that our work with the highly experienced team of medical researchers and other well-known scientists at the ORCLS will provide groundbreaking evidence that the Klotho protein levels in humans are one of several highly critical factors for sustaining human health span, including avoidance of neurological and other age-related disorders."
Dr. Bradley Willcox, MD, MSc, FGSA, FRSM, a leading member of the Okinawa Research Center for Longevity Science, stated that "for the last 50 years, our ORCLS Team, led by Dr. Makoto Suzuki, has been producing groundbreaking research on human aging and longevity. ORCLS scientists created the world's largest, ongoing study of centenarians in the world, discovered the first human longevity genes (Lancet, 1987), and were the first to validate and translate longevity gene findings in mice and other model organisms to humans (PNAS 2008), among other notable discoveries in aging. We have collected and banked biological samples and clinical data, including blood and tissue samples over many years. A selection of these centenarian blood samples will be analyzed in the first phase of our research partnership with KLTO, where we will assess blood levels of the Klotho protein to establish the role of the Klotho protein in promoting longevity and reducing the risks of neurodegenerative diseases, such as ALS, AD and PD, as well as diabetes and cardiovascular disorders."
The Klotho gene was named after the mythologic Greek goddess, Clotho, who was said to "spin the thread of life." The Blue Zones are located in Okinawa, Japan; Ikaria, Greece; the Ogliastra Region of Sardinia; the Nicoya Peninsula in Costa Rica; and Loma Linda, USA.
About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and it's novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Investor Contact and Corporate Communications – Jeffrey LeBlanc, CFOjeff@klothoneuro.com
Website: www.klothoneuro.com.
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/klotho-neurosciences-inc-and-the-okinawa-research-center-for-longevity-science-leading-experts-on-the-okinawa-blue-zone-announce-a-plan-to-study-tissue-levels-of-the-human-klotho-gene-and-protein-in-the-worlds-longest-lived-302489021.html
SOURCE Klotho Neurosciences, Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/24/c5121.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 hours ago
- Medscape
Pricey Drugs Unlikely to Solve Dementia
This transcript has been edited for clarity. Dear colleagues, I'm Christoph Diener from the faculty of medicine at the University of Duisburg-Essen, in Germany. In this month's video, I would like to concentrate on the topic of dementia. We made tremendous progress in the diagnosis of Alzheimer's disease, not only at a time when patients show symptoms but also in the preclinical phase of the disease. Biomarkers and Lifestyle We have new biomarkers in cerebrospinal fluid with amyloid and tau PET, and more recently, we have now biomarkers in plasma. One is p-tau217, and this has shown a high sensitivity for the diagnosis of Alzheimer's disease and a good correlation with cerebrospinal fluid markers, as published recently in Neurology . A second aspect is we know that there are about 14 different lifestyle factors and comorbidities that increase the risk for mild cognitive impairment, dementia, and in particular, Alzheimer's disease. The most frequent ones — as you know — are vascular risk factors, hearing loss, smoking, high alcohol intake,obesity, and nutrition. Unfortunately, for most of these correlations, there have been no prospective randomized trials to show that management or treatment of these risk factors or comorbidities would really decrease the risk of Alzheimer's disease. Just to give you an example, there is one study from the US published in Neurology with more than 100,000 participants, and they showed that consumption of red meat significantly increases the risk of dementia. We have in the past not really considered lifestyle factors enough to prevent Alzheimer's disease. Herpes Zoster and Cognitive Impairment There are very interesting findings on the correlation between Herpes zoster and the increased risk of cognitive impairment and have now several studies with hundreds of thousands of patients in the US, in the UK and Australia, which showed that, if someone has Herpes zoster infection, over the next 13 years, the risk of dementia is increased between 15% and 30%. The more interesting feature is that obviously vaccination against Herpes zoster reduces the risk of have been several studies, including one in Wales with almost 300,000 participants. When the vaccination was introduced, participants born before 1933 were not vaccinated, while 50% of those born after 1933 were vaccinated. After 7 years, the diagnosis of dementia was reduced by 3.5% in vaccinated relative risk reduction for dementia was 20%. Another aspect is which vaccine. The study from the United States with more than 100,000 people observed over 6 years showed that recombinant vaccine is more effective in preventing cognitive impairment and dementia compared to the traditional live vaccine. The risk reduction was 17%. GLP-1 Drugs and Anti-Amyloids We have a totally new class of medicines to treat diabetes and obesity: the GLP-1 receptor agonists. There is indirect evidence that they might also be beneficial for the prevention of dementia. One publication in JAMA Neurology looked at a database of more than 33,000 patients treated with GLP-1 receptor agonistsand 34,000 treated with SGLT2 inhibitors compared with standard therapy. For both substances, there was a 35%-45% reduction in the risk of Alzheimer's dementia and other dementias compared to standard therapy. This has to be shown in one of the ongoing trials with GLP-1 receptor agonists. Let me mention the new beta-amyloid antibodies, lecanemab and donanemab. They have been approved both in the United States and in Europe for the treatment of early stages of Alzheimer's disease. This is a complicated business because you need biomarkers and amyloid PET for the diagnosis, you need regular intravenous administration, and you need MR controls to check for Amyloid-related imaging abnormalities. At the recent Alzheimer's Congress in Toronto, for both substances, long-term data were presented for a time period of three to 4 years. They showed that with increasing time of treatment, there is also an increase, obviously, in efficacy if the data are compared with a database, not within the randomized trials, because these were open-label, long-term studies. With donanemab, it was interesting that, in more than 75% of the patients, there was no longer amyloid detected on PET. The other important issue is that there is now a new application of donanemab that is subcutaneous. Spend Money on Lifestyle At the end of the day. I'm not really sure whether this is an effective treatment if we consider cost and risk, and I think a healthcare system would be better advised to invest all this money into teaching of at-risk persons, in particular, to have an impact on lifestyle. I'm aware that, in low-income people, this is extremely difficult, because they cannot afford healthy food and they cannot afford to pay for a gym for regular exercise. I think we can do much better, in particular, in treating comorbidities like obesity, diabetes, hypertension, high cholesterol, and so on. Dear colleagues, this is a short update on what has happened recently in the field of dementia. I'm Christoph Diener from the University of Duisburg-Essen Medical School. Thank you very much for listening and watching.
Associated Press
6 hours ago
- Associated Press
Jupiter Neurosciences CEO And President Talk About The Power of JOTROL And The Launch of Its Longevity Consumer Line With Benzinga
By Meg Flippin Benzinga DETROIT, MICHIGAN - August 21, 2025 ( NEWMEDIAWIRE ) - Christer Rosen, Chairman and CEO, and Alison Silva, President and CBO at Jupiter Neurosciences Inc. (NASDAQ: JUNS), sat down with Benzinga to discuss how the company is addressing longevity and brain health with JOTROL(TM) and its new direct-to-consumer product line, Nugevia. Jupiter Neurosciences is a clinical-stage pharmaceutical company developing JOTROL, an enhanced orally administered resveratrol formulation known for its antioxidant and anti-inflammatory effects. Resveratrol also activates PARP-1 – an important protein in DNA repair and stress response – improves cardiovascular health, enhances cognitive function, is antibacterial and antiviral against food-borne pathogens. JOTROL is designed and intended to deliver therapeutically relevant, safe levels of resveratrol. Meanwhile Nugevia leverages JOTROL to improve mitochondrial support, mental clarity and 'beauty from within.' 'You can drink 10,000 bottles of red wine per day or take two of our capsules,' to get the resveratrol benefits, Rosen told Benzina during the interview. 'The trick is to get enough in the bloodstream, and the existing products don't do the job. JOTROL is patented all over the world through 2036. We are starting to conquer what we think is going to be a fantastic time for us.' How JOTROL Stands Out While resveratrol has been around for decades and is among the most researched molecules, Silva says achieving therapeutic benefits has proven elusive, mainly due to dosing limitations. To achieve therapeutic benefits, the plasma concentration has to be over 250 nanograms per milliliter, and to get that amount into a product would be impossible without having either severe gastrointestinal (GI) side effects or having to swallow a lot of huge pills. Jupiter Neurosciences was able to reformulate resveratrol and, through clinical trials, demonstrated blood plasma levels 8-10-fold higher than naïve resveratrol with one-tenth the dose. Plus, there were no GI side effects. 'It makes it a key therapeutic for inflammation in the neurodegenerative space, inflammation in the longevity and healthspan space,' said Silva. 'So that's the cracking of the code we believe we have done with JOTROL.' Leveraging JOTROL For The Consumer Market In addition to developing JOTROL to treat central nervous system (CNS) disorders such as Alzheimer's, Parkinson's and rare diseases, the company just launched a direct-to-consumer line, Nugevia, which leverages JOTROL. The idea came to Jupiter Neurosciences about a year ago when the longevity and aging market was getting a lot of attention. Lots of companies were making claims about having supplements backed by clinical data, but the majority, says Rosen, didn't really have the clinical proof – but Jupiter Neurosciences did. 'We're definitely ahead of the curve. We already have a product going into a Parkinson trial, and at the same time, we said why don't we launch a nutraceutical line and have some cash flow. I happened to like cash flow. Biotech is not cash flow,' said Rosen. Nugevia's first three formulations, which it just launched, target mitochondrial support, mental clarity and 'beauty from within' and will be sold via a direct-to-consumer (DTC) model. Nugevia GLO is a daily supplement designed to support radiant, resilient skin from the inside out by promoting cellular defense, collagen integrity and hydration. Nugevia PWR is a daily mitochondrial health supplement scientifically formulated to support cellular energy, endurance and recovery, and Nugevia MND is a scientifically formulated supplement designed to protect and enhance cognitive function and support overall brain health. All three will be available direct-to-consumers in September. Short Sellers Be Forewarned As for when Jupiter Neurosciences will see revenue from its Nugevia product line, Rosen said it will start to materialize this year, next year and more meaningfully in the year after that, once it has more brand ambassadors and key opinion leaders on board and word is out about its products. Jupiter already announced professional golfer Annika Sörenstam – who has won over 95 international tournaments including 72 LPGA titles and 10 major championships – is the company's first brand ambassador, and more will be announced soon. Rosen said potential spokespeople are drawn to the company because of the science behind its products. 'The market doesn't know about it yet, when you look where we are with the stock price,' says the CEO. 'We've been hit by short sellers heavily…we took it as we need to deliver, and when we deliver the share price will take care of itself, and that's what we plan to do and do it sooner than people expect.' Featured image fromShutterstock. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. This content was originallypublished on further disclosureshere.
Yahoo
8 hours ago
- Yahoo
Mizuho Raises Boston Scientific (BSX) Price Target as Robotics and Devices Drive Growth
Boston Scientific Corporation (NYSE:BSX) ranks among the . Mizuho kept its Outperform rating on Boston Scientific Corporation (NYSE:BSX), and increased its price target for the medical device maker from $130 to $140 on July 24. The firm reported that the global recall of the ACURATE transcatheter aortic valve replacement (TAVR) system in the second half of the year was expected to be compensated by solid performance in Boston Scientific's FARAPULSE and WATCHMAN product lines. While Boston Scientific Corporation (NYSE:BSX) has no plans to re-engineer the ACURATE valve, putting it 'at square one in the TAVR space,' the company is still on track to acquire clearances for FARAPULSE in China and Japan before the end of the year, according to Mizuho's research. Boston Scientific Corporation (NYSE:BSX) is a global leader in the manufacture of medical devices, including stents, brain stimulation systems, heart monitors, and catheters. A leading name in robotics, the company has made great strides in the humanoid aspect of the industry with its two-legged Atlas robot. While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
